Loman et al. [158] in 2018 analyzed 25 RTCs (9 used prebiotics, 11 used probiotics, and 7 used synbiotics; n = 1309 patients with NAFLD) and concluded that microbial therapies significantly reduced AST and ALT, but not CRP. This evidence concerns the gene CRP and metabolic dysfunction-associated steatotic liver disease.